Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2326 - 2350 of 3125 in total
Investigational
Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma (NHL).[A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can...
Investigational
A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite hydrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726)
Experimental
AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased after brain damage. Thus, if this drug administered in the acute phase...
Investigational
GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Experimental
AZD-8165 is under investigation in clinical trial NCT01150812 (Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects).
Investigational
Investigational
Investigational
Experimental
Experimental
GSK2018682 has been investigated for the treatment of Multiple Sclerosis, Relapsing-Remitting.
Investigational
Investigational
Investigational
Investigational
Investigational
Experimental
Matched Iupac: … ),3,5,15(19),16-hexaene-8-carboxylic acid ... N-methylacetamido}-3,18-dihydroxy-11-methyl-10,13-dioxo-9,12-diazatricyclo[13.3.1.1^{2,6}]icosa-1(18),2(20
Investigational
Matched Iupac: … methoxy-11',12'-dimethyl-3,4-dihydro-2H-20'-oxa-13'lambda6-thia-1',14'-diazaspiro[naphthalene-1,22'-tetracyclo ... [14.7.2.0^{3,6}.0^{19,24}]pentacosane]-8',16',18',24'-tetraene-13',13',15'-trione ... (1S,3'R,6'R,7'R,8'E,11'S,12'R)-7'-{[(9aR)-octahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methyl}-6-chloro-7'- …
Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is...
Investigational
Plamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)).
Investigational
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy.
Investigational
Anti-GD2 monoclonal antibody 3F8 is under investigation in clinical trial NCT00089258 (Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment).
Investigational
Experimental
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Displaying drugs 2326 - 2350 of 3125 in total